Inhibiting IL-6 in human multiple myeloma
B Klein, ZY Lu, JP Gaillard, JL Harousseau… - Mechanisms in B-Cell …, 1992 - Springer
B Klein, ZY Lu, JP Gaillard, JL Harousseau, R Bataille
Mechanisms in B-Cell Neoplasia 1992: Workshop at the National Cancer Institute …, 1992•SpringerIt has been well established by several groups that IL-6 is overproduced in patients with
Multiple Myeloma (MM) and that this cytokine is an essential growth factor of myeloma cells
both in vitro and in vivo (1–5). Most investigators also agree now that IL-6 is produced
mainly by bone-marrow stromal cells (1, 6). The aim of this report was to summarize our
recent results concerning the mechanisms of IL-6 production control by the bone-marrow
environment and the different means of neutralizing IL-6 activity in vitro and in vivo.
Multiple Myeloma (MM) and that this cytokine is an essential growth factor of myeloma cells
both in vitro and in vivo (1–5). Most investigators also agree now that IL-6 is produced
mainly by bone-marrow stromal cells (1, 6). The aim of this report was to summarize our
recent results concerning the mechanisms of IL-6 production control by the bone-marrow
environment and the different means of neutralizing IL-6 activity in vitro and in vivo.
Abstract
It has been well established by several groups that IL-6 is overproduced in patients with Multiple Myeloma (MM) and that this cytokine is an essential growth factor of myeloma cells both in vitro and in vivo (1–5). Most investigators also agree now that IL-6 is produced mainly by bone-marrow stromal cells (1, 6). The aim of this report was to summarize our recent results concerning the mechanisms of IL-6 production control by the bone-marrow environment and the different means of neutralizing IL-6 activity in vitro and in vivo.
Springer